Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
|
|
|
normal phenotype
|
|
• mice are fertile and show no abnormalities
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
|
|
|
nervous system
|
|
• cerebellar cells transfected with a cre-expressing retrovirus exhibit increased neurospheres compared with wild-type mice
|
neoplasm
|
|
• develop tumors with a similar latency to mice with one wild-type Pgbd5 allele, but most tumors retain an unrecombined floxed Pgbd5 allele
|
nervous system
|
|
• develop tumors with a similar latency to mice with one wild-type Pgbd5 allele, but most tumors retain an unrecombined floxed Pgbd5 allele
|
mortality/aging
|
|
• increased survival compared to mutant mice wild-type for Pgbd5
|
neoplasm
|
|
• up to 70% of mice do not develop medulloblastomas at up to 1 year of life while 79% of mutant mice wild-type for Pgdb5 rapidly develop medulloblastomas
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
Tcf21tm1(cre)Seq mutation
(0 available);
any
Tcf21 mutation
(14 available)
|
|
|
mortality/aging
|
|
• embryos die at varying timepoints between E12.5 and birth
|
renal/urinary system
|
|
• kidneys are comparable in size to controls, display numerous abnormal phenotypes
|
|
|
• multiple cysts are observed, with some cysts containing glomeruli, with other cysts originating in the renal tubules
• cysts arise along entire nephron
|
|
|
• collecting ducts are dilated, distorted and winding, with increased cell proliferation in walls of cysts
|
neoplasm
|
|
• lethality is suggested to result from an aggressive embryonic tumor with minimal renal invasion
|
growth/size/body
|
|
• multiple cysts are observed, with some cysts containing glomeruli, with other cysts originating in the renal tubules
• cysts arise along entire nephron
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
Tg(Atoh1-cre)1Bfri mutation
(1 available)
|
|
|
mortality/aging
|
|
• by 4 weeks, mice start becoming severely ill and must be sacrificed
• all mice die 10 or 11 weeks of age
|
nervous system
|
N |
• neuronal migration to form the laminar architecture and foliation in the cerebellum are normal
|
|
|
• granule neuron precursors exhibit persistent proliferation unlike in wild-type mice
• however, cells are still able to exit the cell cycle
|
|
|
• some regions exhibit nodular structure unlike the discrete layers of cells in wild-type mice
|
|
|
• thickened at P1 to P8 and at P21
• the external granule cell layer persists at P21 unlike in wild-type mice
|
|
|
• at P21 with cerebellar hyperplasia
|
|
|
• increased granule neuron precursors cells at P5
|
neoplasm
cellular
|
|
• granule neuron precursors exhibit persistent proliferation unlike in wild-type mice
• however, cells are still able to exit the cell cycle
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
Tg(Atoh1-cre/Esr1*)14Fsh mutation
(1 available)
|
|
|
mortality/aging
|
|
• by 10 weeks, mice start becoming severely ill and must be sacrificed
• all mice die by 29 weeks of age
|
nervous system
|
|
• granule neuron precursors in mice treated with tamoxifen at P4 exhibit increased proliferation unlike in wild-type mice
|
|
|
• in all mice treated with tamoxifen at E14.5 with a median age of tumor onset at 10 weeks
• in all mice treated with tamoxifen at P4 with a median age of tumor onset at 13 weeks
• in all mice treated with tamoxifen at P8 with a median age of tumor onset at 15.5 weeks
• in 29% of mice treated with tamoxifen at P10 with a median age of tumor onset at 19 weeks
• however, mice treated with tamoxifen at E10.5, at P12, or later than P12 do not develop tumors
|
|
|
• at P21 in mice treated with tamoxifen at P4
|
|
|
• cerebellar hyperplasia at 10 weeks of age
|
neoplasm
|
|
• in all mice treated with tamoxifen at E14.5 with a median age of tumor onset at 10 weeks
• in all mice treated with tamoxifen at P4 with a median age of tumor onset at 13 weeks
• in all mice treated with tamoxifen at P8 with a median age of tumor onset at 15.5 weeks
• in 29% of mice treated with tamoxifen at P10 with a median age of tumor onset at 19 weeks
• however, mice treated with tamoxifen at E10.5, at P12, or later than P12 do not develop tumors
|
cellular
|
|
• granule neuron precursors in mice treated with tamoxifen at P4 exhibit increased proliferation unlike in wild-type mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
Tg(GFAP-cre)25Mes mutation
(2 available)
|
|
|
mortality/aging
|
|
• by 4 weeks, mice become severely ill and must be sacrificed
|
nervous system
|
|
• expanded at E16.5
• thick and disorganized, at birth
|
|
|
• rhombic lip expansion at E16.5
|
|
|
• cerebellar cells exhibit increased neurospheres compared with wild-type mice
|
neoplasm
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptch1tm1Bjw mutation
(2 available);
any
Ptch1 mutation
(115 available)
Tg(KRT14-cre)8Brn mutation
(4 available)
|
|
|
endocrine/exocrine glands
growth/size/body
|
|
• severe growth deficiency such that mice do not progress beyond 49% of control weight, with differences first seen around P19
|
hematopoietic system
homeostasis/metabolism
immune system
integument
|
|
• hyperproliferative lesions first develop in the skin around P19
|
|
|
• mice show rapid development basal cell carcinoma
|
neoplasm
|
|
• mice show rapid development basal cell carcinoma
|
reproductive system
|
|
• mice do not breed successfully
|
Analysis Tools
